Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech A/S Adr (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
$5.06
-$0.02(-2.40%)
At close: 4:00 PM EST
$5.06
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$1.20 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)89.19K
Market Cap
$31.96M
Enterprise Value-$6.42M
Total Cash (Recent Filing)$10.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Apr 07, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding6,316,572
10 Day Avg. Volume43,836
30 Day Avg. Volume89,190
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.75
Price to Sales (P/S)1.36
P/FCF Ratio-0.35
Enterprise Value/Market Cap-0.20
Enterprise Value/Revenue-0.84
Enterprise Value/Gross Profit-0.84
Enterprise Value/Ebitda1.08
Forecast
1Y Price Target
$12.33Price Target Upside143.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$6.10M
Bulls Say, Bears Say
Bulls Say
AI Platform ValidationPIONEER AI model demonstrates the ability to identify clinically relevant neoantigen targets, strengthening confidence in the platform's role in discovering novel cancer vaccine candidates.
Clinical Efficacy And SafetyLead personalized cancer vaccine shows durable clinical responses and a favorable safety profile in advanced melanoma when combined with checkpoint inhibitor therapy, supporting the program's therapeutic potential.
Major Pharma CollaborationExercise of an option by a large pharmaceutical partner validates external interest and creates potential for further collaboration and milestone-driven development support.
Bears Say
Execution And Development RiskDependence on successful preclinical and early clinical results for multiple pipeline candidates creates risk that setbacks could materially delay or impair development progress.
Regulatory, IP And Competitive RiskExposure to regulatory hurdles, intellectual property challenges and intense competition in oncology and infectious disease vaccines could hinder future commercialization prospects.
Valuation ModelRoyalty-focused business model that relies on partnering or out-licensing after early-stage trials can limit near-term revenue visibility and complicate valuation.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $1.20 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $31.96M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Apr 07, 2026 which is in 80 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.02.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 6,316,572 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10.601%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evaxion Biotech Stock Smart Score
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$12.33
▲(143.68% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---